RxDoctor Payments Data

Kimberly Regenhard, APRN

Acute Care · Tulsa, OKNPI 1972268548

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 131 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 10.3% — the pattern of someone who eats at a lot of different presentations.

$2,523in general payments, 2019–2025

Across 131 payments — averaging $19.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$261
  • Irhythm Technologies, Inc.$259
  • Merck$218
  • Novartis$210
  • Boehringer Ingelheim$179
  • Novo Nordisk$177
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$2,523100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,523 in reported general payments places this provider in the 80th percentile of 266 acute care providers in Oklahoma.

See all acute care providers in Oklahoma

Medicare billing

Part B allowed, 2024
$57,381
Medicare patients
463
Services billed
601

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban108$96,675
EntrestoSacubitril/Valsartan81$65,889
FarxigaDapagliflozin Propanediol68$50,173
XareltoRivaroxaban34$29,326
JardianceEmpagliflozin34$20,801
BrilintaTicagrelor23$14,568
Atorvastatin Calcium146$2,425
Metoprolol Succinate199$1,809
Rosuvastatin Calcium99$1,073
ClopidogrelClopidogrel Bisulfate90$881
Carvedilol115$836
Nitroglycerin36$739
Ezetimibe62$728
Amlodipine Besylate90$635
Bumetanide22$603

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$165$96,675108 claims
NovartisEntresto$210$65,88981 claims
AstraZenecaFarxiga, Brilinta$55$64,74191 claims
Johnson & JohnsonXarelto$76$29,32634 claims
Boehringer IngelheimJardiance$179$20,80134 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 266 acute care providers in Oklahoma.

Other acute care in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →